• Je něco špatně v tomto záznamu ?

Effectiveness of first-line anticancer treatment may predict treatment response in further lines in stage III/IV patients with non-small cell lung cancer

M. Bratova, J. Skrickova, M. Matusikova, K. Hrabcova, L. Havel, L. Koubkova, M. Hrnciarik, J. Krejci, O. Fischer, M. Svaton, K. Brat

. 2023 ; 149 (19) : 17123-17131. [pub] 20230928

Jazyk angličtina Země Německo

Typ dokumentu časopisecké články

Perzistentní odkaz   https://www.medvik.cz/link/bmc24000464

PURPOSE: The aim of our study was to evaluate if therapeutic success in the first-line of anticancer treatments in patients with NSCLC may predict treatment success in the following lines. METHODS: We analyzed the data of patients with NSCLC stage III/IV from the TULUNG registry separately for chemotherapy, TKIs, ALK inhibitors, and immunotherapy in the first line during the years 2011-2019. "Succesful treatment " was defined as PFS ≥ 6 months, a "good responder " was a patient with ˃50% of "successful treatment " lines. Treatment responses were analyzed separately for each drug group. Descriptive statistics, Fisher exact test, Pearson Chi-Squared test, log-rank test, and univariate/multivariate logistic regression models were used. RESULTS: The first-line TKI therapy was successful in 66.2%, while good responders accounted for 50.7% of the cohort and their rates were similar for all types of TKIs. First-line platinum-based chemotherapy was successful in 43.1% and 48.6% for combinations with pemetrexed and bevacizumab, respectively. Good responders accounted for 29.5% and 25.9%, respectively. In the group of ALK inhibitors, we observed treatment success in 52.3% of cases, while alectinib showed the highest effectiveness (up to 70%). Good responders constituted 50% of the group. In the first-line immunotherapy group, survival benefit was observed in 52.3%, and good responders constituted 52.3% of the cohort. CONCLUSION: We concluded that the treatment success in first-line therapies in patients with NSCLC may predict survival benefits in the subsequent lines, particularly in EGFR- or ALK-positive disease and immunotherapy-treated patients.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc24000464
003      
CZ-PrNML
005      
20240213093210.0
007      
ta
008      
240109s2023 gw f 000 0|eng||
009      
AR
024    7_
$a 10.1007/s00432-023-05431-5 $2 doi
035    __
$a (PubMed)37768380
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a gw
100    1_
$a Bratova, Monika $u Department of Respiratory Diseases, University Hospital Brno, Jihlavska Street 20, 625 00, Brno, EU, Czech Republic $u Faculty of Medicine, Masaryk University, Brno, Czech Republic
245    10
$a Effectiveness of first-line anticancer treatment may predict treatment response in further lines in stage III/IV patients with non-small cell lung cancer / $c M. Bratova, J. Skrickova, M. Matusikova, K. Hrabcova, L. Havel, L. Koubkova, M. Hrnciarik, J. Krejci, O. Fischer, M. Svaton, K. Brat
520    9_
$a PURPOSE: The aim of our study was to evaluate if therapeutic success in the first-line of anticancer treatments in patients with NSCLC may predict treatment success in the following lines. METHODS: We analyzed the data of patients with NSCLC stage III/IV from the TULUNG registry separately for chemotherapy, TKIs, ALK inhibitors, and immunotherapy in the first line during the years 2011-2019. "Succesful treatment " was defined as PFS ≥ 6 months, a "good responder " was a patient with ˃50% of "successful treatment " lines. Treatment responses were analyzed separately for each drug group. Descriptive statistics, Fisher exact test, Pearson Chi-Squared test, log-rank test, and univariate/multivariate logistic regression models were used. RESULTS: The first-line TKI therapy was successful in 66.2%, while good responders accounted for 50.7% of the cohort and their rates were similar for all types of TKIs. First-line platinum-based chemotherapy was successful in 43.1% and 48.6% for combinations with pemetrexed and bevacizumab, respectively. Good responders accounted for 29.5% and 25.9%, respectively. In the group of ALK inhibitors, we observed treatment success in 52.3% of cases, while alectinib showed the highest effectiveness (up to 70%). Good responders constituted 50% of the group. In the first-line immunotherapy group, survival benefit was observed in 52.3%, and good responders constituted 52.3% of the cohort. CONCLUSION: We concluded that the treatment success in first-line therapies in patients with NSCLC may predict survival benefits in the subsequent lines, particularly in EGFR- or ALK-positive disease and immunotherapy-treated patients.
650    _2
$a lidé $7 D006801
650    12
$a nemalobuněčný karcinom plic $7 D002289
650    12
$a nádory plic $7 D008175
650    _2
$a pemetrexed $x terapeutické užití $7 D000068437
650    _2
$a bevacizumab $x terapeutické užití $7 D000068258
650    _2
$a inhibitory proteinkinas $x terapeutické užití $7 D047428
650    _2
$a erbB receptory $7 D066246
655    _2
$a časopisecké články $7 D016428
700    1_
$a Skrickova, Jana $u Department of Respiratory Diseases, University Hospital Brno, Jihlavska Street 20, 625 00, Brno, EU, Czech Republic $u Faculty of Medicine, Masaryk University, Brno, Czech Republic
700    1_
$a Matusikova, Magda $u Institute of Biostatistics and Analyses, Ltd., Brno, Czech Republic
700    1_
$a Hrabcova, Karolina $u Institute of Biostatistics and Analyses, Ltd., Brno, Czech Republic
700    1_
$a Havel, Libor $u Department of Respiratory Medicine, Thomayer Hospital, Prague, Czech Republic
700    1_
$a Koubkova, Leona $u Department of Pneumology, University Hospital Motol, Prague, Czech Republic $u 2nd Faculty of Medicine, Charles University, Prague, Czech Republic
700    1_
$a Hrnciarik, Michal $u Department of Pneumology, University Hospital Hradec Kralove, Hradec Kralove, Czech Republic $u Faculty of Medicine, Charles University in Prague, Hradec Kralove, Czech Republic
700    1_
$a Krejci, Jana $u Department of Pneumology and Thoracic Surgery, Bulovka Hospital, Prague, Czech Republic
700    1_
$a Fischer, Ondrej $u Department of Respiratory Medicine, University Hospital Olomouc, Olomouc, Czech Republic $u Faculty of Medicine, Palacky University, Olomouc, Czech Republic
700    1_
$a Svaton, Martin $u Department of Pneumology, University Hospital Pilsen, Pilsen, Czech Republic $u Faculty of Medicine, Charles University in Prague, Pilsen, Czech Republic
700    1_
$a Brat, Kristian $u Department of Respiratory Diseases, University Hospital Brno, Jihlavska Street 20, 625 00, Brno, EU, Czech Republic. brat.kristian@fnbrno.cz $u Faculty of Medicine, Masaryk University, Brno, Czech Republic. brat.kristian@fnbrno.cz $u International Clinical Research Center, St. Anne's University Hospital, Brno, Czech Republic. brat.kristian@fnbrno.cz $1 https://orcid.org/000000031674228X
773    0_
$w MED00009972 $t Journal of cancer research and clinical oncology $x 1432-1335 $g Roč. 149, č. 19 (2023), s. 17123-17131
856    41
$u https://pubmed.ncbi.nlm.nih.gov/37768380 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y - $z 0
990    __
$a 20240109 $b ABA008
991    __
$a 20240213093207 $b ABA008
999    __
$a ok $b bmc $g 2049243 $s 1210158
BAS    __
$a 3
BAS    __
$a PreBMC-MEDLINE
BMC    __
$a 2023 $b 149 $c 19 $d 17123-17131 $e 20230928 $i 1432-1335 $m Journal of cancer research and clinical oncology $n J Cancer Res Clin Oncol $x MED00009972
LZP    __
$a Pubmed-20240109

Najít záznam

Citační ukazatele

Možnosti archivace